SCHEDULE: Long Focus Capital Reports 0% Stake in Adaptimmune

Long Focus Capital Management and John Helmers have reported a 0% beneficial ownership stake in Adaptimmune Therapeutics PLC as of December 31, 2025.

Summary

• Long Focus Capital Management, LLC and John Helmers filed a Schedule 13G indicating 0% beneficial ownership of Adaptimmune Therapeutics PLC's American Depositary Shares.
• The filing states that as of December 31, 2025, both reporting persons held 0.00 shares, representing 0% of the class of securities.
• Long Focus Capital Management, LLC is an investment adviser that maintains dispositive and voting power for its clients, but no single client owns more than 5% of the class of securities.
• John Helmers controls Long Focus Capital Management, LLC and is also reported with 0% beneficial ownership.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure, simply reporting a 0% beneficial ownership stake, which provides no new information regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a Schedule 13G filing reporting 0% beneficial ownership by an investment adviser typically indicates a complete divestment of a previous holding or a clarification of a non-holding position. This type of filing does not inherently provide new insights into broader industry trends or competitive dynamics for Adaptimmune Therapeutics PLC.

Stakeholder Impact

• Shareholders: Minimal direct impact as the filing reports no beneficial ownership, suggesting no change in the company's ownership structure from these parties.

Key Dates

Keywords

Adaptimmune Therapeutics, Schedule 13G, Beneficial Ownership, Long Focus Capital Management, John Helmers, ADS, Passive Investment